In order to revise the guidelines, the Task Force reviewed clinical trials presented at the annual scientific meetings of the ACC, AHA, HRS, and European Society of Cardiology in addition to other peer-reviewed, published data.
Results from a real-world study evaluating rivaroxaban (Xarelto; Janssen) in newly diagnosed patients with nonvalvular atrial fibrillation (NVAF) were presented at the American College of Cardiology’s (ACC) 68th Annual Scientific Session.
Researchers found a low rate of recurrent stroke after carotid and vertebral dissection and no difference between antiplatelet agents and anticoagulants.
Study shows comparable rates of functional independence and similar treatment effect with endovascular thrombectomy in patients transferred from an outside hospital vs patients admitted directly.
A large phase 3 trial compared prasugrel (3.75 mg/day) with clopidogrel (75 mg/day) for secondary stroke prevention in patients with noncardioembolic stroke.
Researchers analyzed the causal relevance of lifelong differences in low-density lipoprotein cholesterol for ischemic stroke relative to that for coronary heart disease.
